Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 10/20 | 1.00 |
| ▸ | MAPT | P10636 | 9/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.82 |
| ▸ | LMNA | P02545 | 4/20 | 0.82 |
| ▸ | TP53 | P04637 | 4/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.82 |
| ▸ | USP2 | O75604 | 4/20 | 0.82 |
| ▸ | TSHR | P16473 | 3/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.82 |
| ▸ | NPC1 | O15118 | 2/20 | 0.82 |
| ▸ | RAB9A | P51151 | 2/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.82 |
| ▸ | HPGD | P15428 | 2/20 | 0.82 |
| ▸ | MT-ND4 | P03905 | 2/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amorphigenin SCHEMBL30989228 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTALDH1A1CYP2C19MAPK1 | |
| Amorphigenin SCHEMBL74859 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTALDH1A1CYP2C19MAPK1 | |
| Rotenone SCHEMBL42253 | 0.90 | CYP3A4 (1.00) | CYP3A4MAPTALDH1A1CYP2C19MAPK1 | |
| Rotenone SCHEMBL13845713 | 0.90 | CYP3A4 (1.00) | CYP3A4MAPTALDH1A1CYP2C19MAPK1 | |
| Rotenone SCHEMBL29351552 | 0.90 | CYP3A4 (1.00) | CYP3A4MAPTALDH1A1CYP2C19MAPK1 | |
| Rotenone SCHEMBL20152380 | 0.90 | CYP3A4 (1.00) | CYP3A4MAPTALDH1A1CYP2C19MAPK1 | |
| Rotenone SCHEMBL9815546 | 0.90 | CYP3A4 (1.00) | CYP3A4MAPTALDH1A1CYP2C19MAPK1 | |
| Rotenone SCHEMBL13926662 | 0.90 | CYP3A4 (1.00) | CYP3A4MAPTALDH1A1CYP2C19MAPK1 | |
| Rotenone SCHEMBL19019920 | 0.90 | CYP3A4 (1.00) | CYP3A4MAPTALDH1A1CYP2C19MAPK1 | |
| Rotenone SCHEMBL29388856 | 0.90 | CYP3A4 (1.00) | CYP3A4MAPTALDH1A1CYP2C19MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104523819-B | Amorpha fruticosa extract and preparation method thereof | 广东医学院 | 2018-11-13 | — | — | CN | claimed |
| CN-108135818-A | Contain the skin-whitening composition of Amorphigenin as active ingredient | 庆尚大学校产学协力团 | 2018-06-08 | — | — | CN | claimed |
| CN-118339274-A | Brandy replica | 艾娃食品实验室股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| WO-2023055801-A1 | BRANDY REPLICAS | AVA FOOD LABS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| EP-3363426-B1 | COMPOSITION FOR SKIN WHITENING CONTAINING AMORPHIGENI AS ACTIVE INGREDIENT | NAT UNIV GYEONGSANG IACF (KR) | 2021-06-16 | — | — | EP | disclosed |
| EP-3363426-B1 | COMPOSITION FOR SKIN WHITENING CONTAINING AMORPHIGENI AS ACTIVE INGREDIENT | NAT UNIV GYEONGSANG IACF (KR) | 2021-06-16 | — | — | EP | disclosed |
| US-20200188361-A1 | USE OF MITOCHONDRIAL ACTIVITY INHIBITORS FOR THE TREATMENT OF POOR PROGNOSIS ACUTE MYELOID LEUKEMIA | UNIVERSITE DE MONTREAL (CA) | 2020-06-18 | — | — | US | disclosed |
| US-20190192488-A1 | USE OF MITOCHONDRIAL ACTIVITY INHIBITORS FOR THE TREATMENT OF POOR PROGNOSIS ACUTE MYELOID LEUKEMIA | Université de Montréal (CA) | 2019-06-27 | — | — | US | disclosed |
| EP-3493802-A1 | USE OF MITOCHONDRIAL ACTIVITY INHIBITORS FOR THE TREATMENT OF POOR PROGNOSIS ACUTE MYELOID LEUKEMIA | Université de Montréal (CA) | 2019-06-12 | — | — | EP | disclosed |
| CN-109689051-A | Mitochondria activity inhibitor is used to treat the purposes of poor prognosis acute myeloid leukaemia | 蒙特利尔大学 | 2019-04-26 | — | — | CN | disclosed |
| CN-104523819-B | Amorpha fruticosa extract and preparation method thereof | 广东医学院 | 2018-11-13 | — | — | CN | disclosed |
| WO-2010134039-A2 | MITOCHONDRIAL ACTIVITY INHIBITORS OF CANCER-INITIATING CELLS AND USE THEREOF | UNIVERSITE DE GENEVE (CH) | 2010-11-25 | — | — | WO | disclosed |
| US-20090142471-A1 | PLANT ISOFLAVONOID HYDROXYLASES AND METHODS OF USE THEREOF | NOBLE RESEARCH INSTITUTE, LLC | 2009-06-04 | — | — | US | disclosed |
| WO-2008133730-A2 | LABELED ROTENONE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080267948-A1 | Croos-B Structure Binding Compounds | CROSSBETA BIOSCIENCES B.V. (NL) | 2008-10-30 | — | — | US | disclosed |
| US-20080267948-A1 | Croos-B Structure Binding Compounds | CROSSBETA BIOSCIENCES B.V. (NL) | 2008-10-30 | — | — | US | disclosed |
| US-7442851-B2 | Plant isoflavonoid hydroxylases and methods of use thereof | THE SAMUEL ROBERTS NOBLE FOUNDATION (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1720986-A2 | PLANT ISOFLAVONOID HYDROXYLASES AND METHODS OF USE THEREOF | THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20050172354-A1 | Plant isoflavonoid hydroxylases and methods of use thereof | THE SAMUEL ROBERT NOBLE FOUNDATION | 2005-08-04 | — | — | US | disclosed |
| WO-2005042747-A2 | PLANT ISOFLAVONOID HYDROXYLASES AND METHODS OF USE THEREOF | THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267948-A1 | Croos-B Structure Binding Compounds | CACYBP, TBCB, MYCBP | CYP3A4 3998/4885MAPT 2206/4885ALDH1A1 3494/4885 |
| US-20200188361-A1 | USE OF MITOCHONDRIAL ACTIVITY INHIBITORS FOR THE TREATMENT OF POOR PROGNOSIS ACUTE MYELOID LEUKEMIA | NPM1, TFAM, NDUFAF1 | CYP3A4 2695/4885MAPT 4312/4885ALDH1A1 3326/4885 |
| US-20190192488-A1 | USE OF MITOCHONDRIAL ACTIVITY INHIBITORS FOR THE TREATMENT OF POOR PROGNOSIS ACUTE MYELOID LEUKEMIA | IDH2, TFAM, NUTF2 | CYP3A4 2838/4885MAPT 4337/4885ALDH1A1 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.